View Gilead Sciences, Inc. (GILD) current and estimated P/E ratio data provided by Seeking Alpha.

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Shares of Gilead Sciences Inc. GILD inched 0.33% higher to $84.95 Friday, on what proved to be an all-around great trading ...

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...

Investors in Gilead Sciences Inc (Symbol: GILD) saw new options become available today, for the November 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

The drugmaker Gilead Sciences on Wednesday announced a plan to allow six generic pharmaceutical companies in Asia and North ...

The stock's fall snapped a five-day winning streak.

After years of demands from shareholders for another major deal, Gilead has made a spectacular move, sealing a deal to acquire cell therapy leader Kite for just under $12 billion. Gilead had been ...

Co-founder Finny Kuruvilla manages the firm’s largest two funds — Eventide Gilead and Eventide Healthcare and Life Sciences — and remains the firm’s largest owner, though more than 20 of ...

After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S. The California biotech announced the decision ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the health care sector on Friday, sending the drugmaker's stock price soaring while ...